ArticleJournal of pharmacopuncture2020
Comparing the Therapeutic Effects of
Article in Journal of pharmacopuncture, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- A Comprehensive Systematic Review of Natural Biomedicines for Immune-Mediated and Inflammatory Dermatologic Diseases.Clinical drug investigation · 2025Pooled it
- Article
- Advanced delivery of natural bioactive compounds for atopic dermatitis: a review of polymeric conjugates and nanocarriers.Natural products and bioprospecting · 2026Review
- The efficacy of psyllium combined with aloe vera in treating sand accumulation in equine intestines.Open veterinary journal · 2026Article
- Skin Barrier Repair and Nursing Care in Patients with Atopic Dermatitis: A Narrative Review.International journal of general medicine · 2025Review
- Recent Advances in Phytochemical-Based Topical Applications for the Management of Eczema: A Review.International journal of molecular sciences · 2024Review
- The effect of various interventions on the prevention of radiation dermatitis: a network meta-analysis.American journal of translational research · 2024Review
- Efficacy and Tolerability of a Novel Topical Treatment Containing Pea Protein and Xyloglucan in the Management of Atopic Dermatitis in Children: A Prospective, Multicenter Clinical Study.Dermatology and therapy · 2023Article
- Topical Application of a Formulation Containing Pea Proteins and Xyloglucan in Adult Patients with Atopic Dermatitis: A Double-blind, Parallel, Randomized, Placebo-controlled, Multicenter Study.The Journal of clinical and aesthetic dermatology · 2023Article
- Evidence for Natural Products as Alternative Wound-Healing Therapies.Biomolecules · 2023Review
- Comparative Evaluation of the Effect of Aloe Vera Gel, Olive Oil, and Compound Aloe Vera Gel-Olive Oil on Prevention of Pressure Ulcer: A Randomized Controlled Trial.Advanced biomedical research · 2022Article
- Anti-Inflammatory and Restorative Effects of Olives in Topical Application.Dermatology research and practice · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesAtopic dermatitis (AD) is a prevalent and chronic, pruritic inflammatory skin condition that can influence all age groups. AD is associated with a poor health-related quality of life. This randomized clinical trial was performed to compare the effectiveness of Olivederma (combination of
methodsThirty-six AD patients were randomly allocated to topical Olivederma or betamethasone, and were followed for 6 weeks.
resultsTotal SCORAD severity scores showed significant decrease in both groups, while it was more prominent in Olivederma group (64.5% improvement in Olivederma vs. 13.5% improvement in Betamethasone, p-value < 0.001). Quality of life (DLQI questionnaire) of AD patients was significantly improved after 6 weeks treatment with Betamethasone (22.3%, p < 0.001) and Olivederma (60.7%, p-value < 0.001). Olivederma group showed a significantly lower DLQI score in comparison with Betamethasone treated patients after 6 weeks of therapy (p < 0.001). Improvements in eosinophil count and serum IgE was observed.
conclusionIn summary, this study shows that Olivederma is superior to topical Betamethasone after 6 weeks of therapy with regard to disease severity, quality of life and eosinophil count.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.